当前,非小细胞肺癌已经成为威胁人类生命健康的恶性肿瘤之一,其发病初期症状并不明显,一旦发现肿瘤则意味着病情已进入晚期,且失去了手术机会,为患者及其家属带来了巨大的心理伤害。对于无法进行手术的非小细胞肺癌主要以化疗治疗为主,近年来出现了多种靶向治疗药物,也进一步提升了肺癌的治疗效果。恩度是我国自主研发的血管内皮抑制素,它在治疗癌症过程中起到了很好的效果,但国内却并未对其进行系统评价。本文则系统性评价了恩度联合化疗治疗非小细胞肺癌的安全性,以期为后期的治疗提供更多依据。 Currently, non-small cell lung cancer has become one of the malignant tumors that threaten the health of human beings. Its symptoms are not obvious at the initial stage of the disease. Once the tumor is found, it means the disease has advanced and has lost the chance of surgery, bringing patients and their families A huge psychological damage. For non-surgical non-small cell lung cancer mainly chemotherapy treatment, in recent years a variety of targeted therapies, but also further enhance the therapeutic effect of lung cancer. Endurance is our own research and development of endostatin, it has played a very good effect in the treatment of cancer, but it has not been systematically evaluated in China. This article systematically evaluated the safety of Endo combined with chemotherapy in the treatment of non-small cell lung cancer, with a view to provide more evidence for the treatment later.